SCHEMBL3250273

SCHEMBL3250273

CCOC(=O)/C=C/c1ccc2[nH]c(=O)c3[nH]cc(C(=O)OCC)c3c2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTR P02766 1/20 0.45
DPP4 P27487 1/20 0.45
P2RY12 Q9H244 1/20 0.44
NPC1 O15118 1/20 0.44
CASP3 P42574 1/20 0.44
RAB9A P51151 1/20 0.44
SENP8 Q96LD8 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
SENP6 Q9GZR1 1/20 0.44
GABRA1 P14867 2/20 0.43
GABRB2 P47870 2/20 0.43
GABRB1 P18505 1/20 0.42
GABRA3 P34903 1/20 0.42
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA7 P43166 1/20 0.42
CA9 Q16790 1/20 0.42
CA14 Q9ULX7 1/20 0.42
CLEC4M Q9H2X3 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3250274 1.00 TTR (0.45) TTRDPP4P2RY12NPC1CASP3
SCHEMBL3246027 0.92 TTR (0.45) TTRDPP4P2RY12NPC1CASP3
SCHEMBL3248903 0.92 TTR (0.45) TTRDPP4P2RY12NPC1CASP3
SCHEMBL3255436 0.88 GABRA1 (0.45) NPC1RAB9AGABRA1GABRB2GABRB1
SCHEMBL3255440 0.88 GABRA1 (0.45) NPC1RAB9AGABRA1GABRB2GABRB1
SCHEMBL3253948 0.85 GABRA1 (0.37) P2RY12GABRA1GABRB2GABRB1GABRA3
SCHEMBL3255449 0.84 TTR (0.43) TTRDPP4P2RY12NPC1CASP3
SCHEMBL3253944 0.84 SMN1; SMN2 (0.38) GABRA1GABRB2GABRB1GABRA3CLEC4M
SCHEMBL3253941 0.84 SMN1; SMN2 (0.38) GABRA1GABRB2GABRB1GABRA3CLEC4M
SCHEMBL3249067 0.84 ALOX15 (0.49) GABRA1GABRB2GABRB1GABRA3CLEC4M

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1899335-B1 PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS PF MEDICAMENT (FR) 2010-05-19 EP claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 TTR 4191/4885DPP4 3997/4885P2RY12 2891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.